Application of MR/PET in oncologic imaging;Einsatz von MR/PET in der onkologischen Bildgebung

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 184, Issue 9, 2012, Pages 780-787

  Schwenzer, N F ^a   Pfannenberg, C ^a   Reischl, G ^a   Werner, M K ^a   Schmidt, H ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

MR imaging; MR PET; PET; PET CT

Indexed keywords

TRACER;

ARTICLE; CARDIAC IMAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; FUNCTIONAL NEUROIMAGING; HEALTH CARE COST; HUMAN; IMAGE PROCESSING; IMAGING; LUNG; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIC IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON SPECTROSCOPY; SPECTROSCOPY;

HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SUBTRACTION TECHNIQUE;

EID: 84865706319     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0031-1299334     Document Type: Article

References (60)

1. De Ponti E, Morzenti S, Guerra L et al. Performance measurements for the PET/CT Discovery-600 using NEMA NU 2-2007 standards. Med Phys: 2011; 38 968 974
2. Delso G, Furst S, Jakoby B et al. Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner. J Nucl Med: 2011; 52 1914 1922
3. Schober O, Heindel W. PET-CT Hybrid Imaging. Stuttgart Thieme: 2010
4. Zaidi H, Ojha N, Morich M et al. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol: 2011; 56 3091 3106
5. Fischer BM, Lassen U, Hojgaard L. PET-CT in preoperative staging of lung cancer. N Engl J Med: 2011; 364 980 981
6. Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res: 2010; 10 283
7. Pawaroo D, Cummings NM, Musonda P et al. Non-small cell lung carcinoma: accuracy of PET/CT in determining the size of T1 and T2 primary tumors. Am J Roentgenol: 2011; 196 1176 1181
8. Shiraishi K, Nomori H, Ohba Y et al. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography. Ann Thorac Cardiovasc Surg: 2010; 16 394 400
9. Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol: 2011; 727 33 51
10. Fischer B, Lassen U, Mortensen J et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med: 2009; 361 32 39
11. Peric B, Zagar I, Novakovic S et al. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer: 2011; 11 328
12. Strobel K, Skalsky J, Kalff V et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging: 2007; 34 1366 1375 (Pubitemid 47312588)
13. Picchio M, Briganti A, Fanti S et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol: 2011; 59 51 60
14. Souvatzoglou M, Krause BJ, Purschel A et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol: 2011; 99 193 200
15. Picchio M, Messa C, Landoni C et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol: 2003; 169 1337 1340 (Pubitemid 36323779)
16. Rinnab L, Mottaghy FM, Simon J et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int: 2008; 81 191 197
17. Scattoni V, Picchio M, Suardi N et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol: 2007; 52 423 429 (Pubitemid 46963456)
18. Chowdhury FU, Bradley KM, Gleeson FV. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Clin Radiol: 2008; 63 1297 1309
19. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med: 2006; 36 169 181 (Pubitemid 43320452)
20. Flamen P, Lerut A, Van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol: 2000; 18 3202 3210
21. Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. Methods Mol Biol: 2011; 727 59 76
22. Cashen AF, Dehdashti F, Luo J et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med: 2011; 52 386 392
23. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol: 2007; 25 579 586 (Pubitemid 350002966)
24. Herrmann K, Buck AK, Schuster T et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med: 2011; 52 690 696
25. Juweid ME. FDG-PET/CT in lymphoma. Methods Mol Biol: 2011; 727 1 19
26. Trotman J, Fournier M, Lamy T et al. Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. J Clin Oncol: 2011; 29 3194 3200
27. Ciernik IF, Dizendorf E, Baumert BG et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys: 2003; 57 853 863 (Pubitemid 37194314)
28. Gehler B, Paulsen F, Oksuz MO et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol: 2009; 4 56
29. Mac Manus MP, Hicks RJ, Ball DL et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer: 2001; 92 886 895 (Pubitemid 32783077)
30. Patel CN, Nazir SA, Khan Z et al. 18F-FDG PET/CT of cervical carcinoma. Am J Roentgenol: 2011; 196 1225 1233
31. Sironi S, Buda A, Picchio M et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology: 2006; 238 272 279 (Pubitemid 43010605)
32. Xue F, Lin LL, Dehdashti F et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol: 2006; 101 147 151
33. Cetina L, Serrano A, Cantu-de-Leon D et al. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. Rev Invest Clin: 2011; 63 227 235
34. Kitajima K, Murakami K, Yamasaki E et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging: 2009; 36 362 372
35. Lai CH, Huang KG, See LC et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer: 2004; 100 544 552
36. Pallardy A, Bodet-Milin C, Oudoux A et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging: 2010; 37 1270 1278
37. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET IIIo", 21 July and 19 September 2000. Eur J Nucl Med: 2001; 28 1707 1723 (Pubitemid 33036116)
38. IQWiG PET und PET/CT bei malignem Melanom. Abschlussbericht D06-01F.: 2011
39. Catana C, Procissi D, Wu Y et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A: 2008; 105 3705 3710 (Pubitemid 351723462)
40. Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med: 2008; 14 459 465 (Pubitemid 351499385)
41. Pichler BJ, Judenhofer MS, Catana C et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med: 2006; 47 639 647 (Pubitemid 46768465)
42. Schlemmer HP, Pichler BJ, Schmand M et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology: 2008; 248 1028 1035
43. Bisdas S, Nagele T, Schlemmer HP et al. Switching on the lights for real-time multimodality tumor neuroimaging: The integrated positron-emission tomography/MR imaging system. Am J Neuroradiol: 2010; 31 610 614
44. Boss A, Bisdas S, Kolb A et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med: 2010; 51 1198 1205
45. Boss A, Stegger L, Bisdas S et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol: 2011; 21 1439 1446
46. Bookheimer SY, Zeffiro TA, Blaxton T et al. A direct comparison of PET activation and electrocortical stimulation mapping for language localization. Neurology: 1997; 48 1056 1065
47. Cai W, Chen K, Mohamedali KA et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med: 2006; 47 2048 2056 (Pubitemid 47544993)
48. Chen K, Cai W, Li ZB et al. Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol: 2009; 11 15 22
49. von Schulthess GK, Burger C. Integrating imaging modalities: what makes sense from a workflow perspective? Eur J Nucl Med Mol Imaging: 2010; 37 980 990
50. Coombs BD, Szumowski J, Coshow W. Two-point Dixon technique for water-fat signal decomposition with B0 inhomogeneity correction. Magn Reson Med: 1997; 38 884 889 (Pubitemid 27508631)
51. Martinez-Moller A, Souvatzoglou M, Delso G et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med: 2009; 50 520 526
52. Keereman V, Holen RV, Mollet P et al. The effect of errors in segmented attenuation maps on PET quantification. Med Phys: 2011; 38 6010
53. Hofmann M, Steinke F, Scheel V et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med: 2008; 49 1875 1883
54. Boss A, Kolb A, Hofmann M et al. Diffusion tensor imaging in a human PET/MR hybrid system. Invest Radiol: 2010; 45 270 274
55. Eiber M, Souvatzoglou M, Pickhard A et al. Simulation of a MR-PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. Eur J Radiol 10.1016/j.blov.2011.03.031
56. Pfannenberg C, Aschoff P, Schanz S et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer: 2007; 43 557 564 (Pubitemid 46177588)
57. Orcurto V, Denys A, Voelter V et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Melanoma Res: 2012; 22 63 69
58. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med: 2010; 363 711 723
59. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med: 2010; 363 809 819
60. Strauss LG, Dimitrakopoulou-Strauss A. Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases? Eur J Nucl Med Mol Imaging: 2007; 34 1902 1905 (Pubitemid 350212150)